Bicara Therapeutics BCAX Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount.
The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's valuation allowance, deferred tax asset, increase (decrease), amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's valuation allowance, deferred tax asset, increase (decrease), amount?
- Bicara Therapeutics (BCAX) reported valuation allowance, deferred tax asset, increase (decrease), amount of $9.7M in Q4 2025.
- What does valuation allowance, deferred tax asset, increase (decrease), amount mean?
- This metric tracks the net change in the valuation allowance established against deferred tax assets. It reflects the company's periodic reassessment of its ability to utilize tax assets like net operating loss carryforwards. A consistent increase in this allowance often signals ongoing uncertainty regarding future profitability.